SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
February 24, 2011
Date of Report (Date of earliest event reported)
Medicis Pharmaceutical Corporation
(Exact name of registrant as specified in its charter)
(State of Incorporation)
(Commission File Number)
(IRS Employer Identification Number)
7720 North Dobson Road
Scottsdale, Arizona 85256
(Address of principal executive offices) (Zip Code)
(Registrants telephone number, including area code)
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
Item 1.01 Entry into a Material Definitive Agreement.
On February 24, 2011, Medicis Pharmaceutical Corporation (the Company) entered into a
Settlement Agreement (Settlement Agreement) with Barr Laboratories, Inc. (Barr), a subsidiary
of Teva Pharmaceuticals USA, Inc., on behalf of itself and certain of its affiliates, including
Teva Pharmaceuticals USA, Inc. (collectively, Teva). Under the terms of the Settlement
Agreement, the Company agreed to grant to Teva a future license to make and sell its generic
versions of SOLODYN® (minocycline HCl, USP) Extended Release Tablets in 65mg and 115mg strengths
under the SOLODYN intellectual property rights belonging to the Company, with the license grant
effective in February 2018, or earlier under certain conditions. The Company also agreed to grant
to Teva a future license to make and sell generic versions of SOLODYN in 55mg, 80mg and 105mg
strengths under the Companys SOLODYN intellectual property rights, with the license grant
effective in February 2019, or earlier under certain conditions. The Settlement Agreement provides
that Teva will be required to pay the Company royalties based on sales of Tevas generic SOLODYN
products pursuant to the foregoing licenses.
Pursuant to the Settlement Agreement, the companies agreed to terminate all legal disputes
between them relating to SOLODYN. In addition, Teva confirmed that the Companys patents relating
to SOLODYN are valid and enforceable, and cover Tevas activities relating to Tevas generic
SOLODYN products under Abbreviated New Drug Application No. 65-485 and any amendments and
supplements thereto. Teva also agreed to be permanently enjoined from any distribution of generic
SOLODYN products in the U.S. except as described above.
Item 2.02 Results of Operations and Financial Condition.
On February 25, 2011, the Company issued a press release announcing its financial results for
the quarter and year ended December 31, 2010. A copy of the press release is furnished herewith as
Exhibit 99.1 and is incorporated by reference herein.
The information in this Item 2.02, including the accompanying exhibit, is being furnished and
shall not be deemed filed for the purposes of Section 18 of the Securities Exchange Act of 1934,
as amended, or otherwise subject to the liabilities of that Section. The information in this Item
2.02 shall not be incorporated by reference into any registration statement or other document filed
pursuant to the Securities Act of 1933, as amended, regardless of any general incorporation
language in such filing.
Item 9.01 Exhibits.
||Press Release dated February 25, 2011.